ALK-abello

Danish allergy‑solutions leader ALK‑Abelló markets injectable, sublingual, and tablet immunotherapies—GRAZAX, RAGWIZAX, MITICURE, CEDARCURE, ITULAZAX—plus diagnostics and a digital platform, driving growth in the expanding allergic‑disease market.

Headquarters: Denmark (DNK)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 2,764
HQ: Horsholm

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
ALK-B	ALK-abello Class A/S Cap: 48.6B \| P/E: 44.1	EQUITY	CPH	DKK	DK0060027142	Active	📈